Business Context and Reporting Period
Company: Immunic, Inc. (formerly Vital Therapies, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: July 16, 2019 (Earliest event reported: July 17, 2019)
Reporting Period: This filing reports specific corporate events occurring in July 2019 and provides updates on the company's business status following a reverse merger completed in April 2019.
Immunic is a clinical-stage biopharmaceutical company focused on developing selective oral therapies for chronic inflammatory and autoimmune diseases. The company operates primarily from Planegg-Martinsried, Germany, and has 18 employees. It is an emerging growth company listed on the Nasdaq Capital Market under the symbol "IMUX."
Key Financial Metrics
Revenue: The filing states that Immunic has not generated any revenue from commercial sales of its product candidates to date.
Profitability and Losses:
- Net loss for the year ended December 31, 2018: $41.5 million.
- Net loss for the year ended December 31, 2017: $52.1 million.
- Accumulated deficit as of March 31, 2019: $346.9 million.
Cash Flow and Liquidity:
- Net cash used in operating activities for 2018 and 2017 was $9.7 million each year.
- The company believes its existing cash and cash equivalents will fund operations into the third quarter of 2020.
Debt: The filing does not specify outstanding debt levels but notes that the company has financed operations primarily through the sale of equity securities.
Material Changes and Recent Developments
Capital Raising (Item 1.01): On July 17, 2019, Immunic entered into a Sales Agreement with SVB Leerink LLC. Under this "at-the-market" offering, the company may sell up to $40,000,000 of its common stock. Proceeds are intended to fund clinical development and general corporate purposes. The company pays a 3.0% commission on gross proceeds.
Corporate Governance Changes (Item 5.03):
- Certificate of Incorporation: Amended to eliminate 75% supermajority voting requirements for director changes, special meetings, and affiliate transactions, replacing them with majority approval standards.
- Bylaws: Amended to reflect the name change from Vital Therapies, Inc. to Immunic, Inc., and to eliminate the concept of a lead director.
Recent Transaction History (Item 8.01):
- Completed a reverse merger with Immunic AG in April 2019, resulting in Immunic AG becoming a wholly-owned subsidiary.
- Effectuated a 40-for-1 reverse stock split immediately prior to the exchange.
- Terminated a prior sales agreement with Cantor Fitzgerald & Co. effective July 19, 2019.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Product Pipeline: Immunic is pursuing three main programs: IMU-838 (DHODH inhibitor for RRMS and IBD), IMU-935 (RORγt inverse agonist for psoriasis), and IMU-856 (intestinal barrier function modulator).
- Clinical Timeline:
- IMU-838: Phase 2b trials ongoing in Ulcerative Colitis (CALDOSE-1) and Relapsing-Remitting Multiple Sclerosis (EMPhASIS). A Phase 2b trial in Crohn's Disease (CALDOSE-2) is expected to start in the second half of 2019.
- IMU-935: First-in-man trials expected to start in September 2019.
- IMU-856: First-in-man trials expected in the first half of 2020.
- Financial Outlook: The company anticipates continuing to incur significant and increasing losses for the foreseeable future and expects to require substantial additional funding.
Risks and Contingencies:
- Profitability: No assurance of ever achieving profitability; dependent on regulatory approval and commercialization.
- Capital Needs: Failure to obtain additional capital could force delays or termination of development programs.
- Internal Controls: The company identified a material weakness in internal control over financial reporting related to equity-based compensation accounting for the year ended December 31, 2018.
- Regulatory: Clinical trials are inherently uncertain; failure to meet endpoints or safety issues could halt development.
Key Facts for Investor Verification
- Cash Runway: Verify the company's current cash position against the stated projection of funding operations only into the third quarter of 2020.
- Capital Raise Execution: Monitor the actual volume and pricing of shares sold under the new $40 million SVB Leerink Sales Agreement.
- Clinical Milestones: Track enrollment and interim analysis results for the IMU-838 Phase 2b trials (CALDOSE-1 and EMPhASIS), as these are critical for future funding and valuation.
- Internal Controls Remediation: Review subsequent filings (10-K/10-Q) to confirm the remediation of the material weakness in internal controls over financial reporting.
- Accumulated Deficit: Note the significant accumulated deficit of $346.9 million as of March 31, 2019, indicating a history of substantial losses.